Lung cancer and mesothelioma caused 4,147 deaths in Scotland in 2009, and deaths of women from thedisease increased by 12% in the preceding decade, despite a corresponding fall of 20% among men.
Dr Chris Carter, (right) a senior lecturer the Strathclyde Institute of Pharmacy and Biomedical Sciences, led the research, partnered by Professor Alex Mullen and Dr Valerie Ferro. She said: "Increasing awareness of cancer risks and improvements in treatment do not alter the fact that it remains one of Scotland's biggest killers and lung cancer is its most common form. This means that new, improved treatments are still essential.
"By delivering cisplatin, one of the most widely used drugs for lung cancer, in a vaporised form, we would be able to get it to the cancerous cells and avoid the damage to healthy cells which can be hugely debilitating to patients. It would make the treatment far less onerous for them and we hope it would help them to live longer."
The pioneering work of the Strathclyde Institute of Pharmacy and Biomedical Sciences in developing new medicines for illnesses and conditions including infectious diseases, cancer, heart disease, and schizophrenia has resulted in an £8m fundraising campaign underway for the Institute's new £36m building, to expand and enhance its innovative research and education in medicine discovery, development and use.